PA · ALBIO.PA
Biosynex S.A.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Illkirch-Graffenstaden 67400
- Website
- biosynex.com
Price · as of 2024-12-31
$0.81
Market cap 17.14M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $17.40 | +2,048.15% |
| Intrinsic Value(DCF) | $0.64 | -20.99% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $7.87 | $1,428,938.05 | $0.00 | $0.00 | |
| 2014 | $3.79 | $123.53 | $342,371.33 | $0.00 | $0.00 |
| 2015 | $2.75 | $81.09 | $370,219.97 | $1.66 | $0.00 |
| 2016 | $3.69 | $50.94 | $1,255,833.99 | $0.10 | $0.00 |
| 2017 | $3.32 | $94.24 | $2,353.90 | $0.81 | $0.70 |
| 2018 | $2.80 | $26.71 | $18.32 | $1.00 | $0.61 |
| 2019 | $4.13 | $47.67 | $0.69 | $0.91 | $2.06 |
| 2020 | $16.14 | $645.46 | $7,039.55 | $21.18 | $1,173.82 |
| 2021 | $14.98 | $121.61 | $1,040,157.05 | $59.37 | $1,514.72 |
| 2022 | $11.60 | $143.31 | $4,539.33 | $0.00 | $0.00 |
| 2023 | $5.77 | $321.58 | $0.00 | $0.00 | $120.73 |
| 2024 | $1.61 | $17.40 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Biosynex S.A.'s (ALBIO.PA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $17.40
- Current price
- $0.81
- AI upside
- +2,048.15%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.64
-20.99% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Biosynex S.A.
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
- CEO
- Larry Abensur
- Employees
- 515
- Beta
- 0.83
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.64 ÷ $0.81) − 1 = -20.99% (DCF, example).